Devonian Health Group appoints Kathryn Gregory to its Board of Directors

– CANADA, Quebec City –  Devonian Health Group Inc. (TSXV: GSD / OTC: DVHGF), a clinical-stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the appointment of Kathryn Gregory to its Board of Directors, effective February 28, 2024.

About Kathryn J. Gregory

Kathryn Gregory has over 25 years of executive leadership experience in startup, mid-sized, and large pharmaceutical and biotechnology companies. She has extensive experience in international business development including corporate strategy, licensing, mergers and acquisitions, alliance management, and operational expertise in marketing, strategic sourcing, and procurement. Ms. Gregory serves as Head of Business Development at Rgenta Therapeutics, Inc., a small molecule ribonucleic acid modulation company, and concurrently as CBO of reVision Therapeutics, Inc., a startup ophthalmology company. Ms. Gregory currently serves as director of Carmell Corporation, a bio-aesthetics company focused on topical skin and hair care. Over her career, Ms. Gregory has led global business development functions for several pharmaceutical companies of all sizes.

She received an M.B.A. from Pepperdine University and a B.A. degree from the University of California, Berkeley.

About Devonian

Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by the American Food and Drug Administration’s set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the-art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential.

For more information: https://groupedevonian.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.